A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 18 Jun 2018 Status changed from active, no longer recruiting to completed.
- 17 May 2018 Planned End Date changed from 4 May 2018 to 15 Jun 2018.
- 17 May 2018 Planned primary completion date changed from 4 May 2018 to 15 Jun 2018.